Business Context and Reporting Period
Universe Pharmaceuticals INC, a Cayman Islands exempted company, filed this Form 6-K for the month of June 2026. The filing discloses the entry into a Share Purchase Agreement (SPA) dated June 17, 2026, to acquire 100% of the issued shares of Best Praise International Limited ("Target"). The Target holds five patents in the People's Republic of China related to pharmaceutical compounds and drug delivery technologies for age-related diseases, neurodegenerative conditions, cognitive disorders, and cardiovascular applications.
Key Financial Metrics
This filing is a current report regarding a corporate transaction and does not contain audited financial statements, revenue, profit, cash flow, or liquidity metrics for the reporting period.
- Acquisition Consideration: US$10,751,000.
- Payment Method: Issuance of 4,376,552 Class A ordinary shares (Consideration Shares).
- Valuation Basis: Determined by an independent valuation report from King Kee Appraisal and Advisory Limited.
Material Changes
The primary material change is the agreement to acquire intellectual property assets to complement the Company's existing pharmaceutical business. The Board of Directors ratified and approved the transaction on June 24, 2026. The Consideration Shares are issued as restricted securities and are subject to resale registration provisions.
Outlook, Risks, and Contingencies
The closing of the acquisition is subject to customary conditions precedent, including internal approvals, SEC and Nasdaq compliance, legal opinions on patent validity, and confirmation that the transaction will not result in a change of control.
- Termination Rights: Either party may terminate the SPA if conditions are not satisfied within 120 days of execution. The Company may also terminate unilaterally for material breach, inaccuracy in representations, or material adverse change in the Target's business.
- Risks: Forward-looking statements are subject to risks including failure to satisfy closing conditions, inability to obtain regulatory approvals, and failure to realize anticipated benefits.
Investor Verification Checklist
- Verify the final valuation report from King Kee Appraisal and Advisory Limited.
- Confirm the legal opinion from PRC counsel regarding the validity and ownership of the Target's five patents.
- Monitor the satisfaction of SEC and Nasdaq compliance procedures for the issuance of 4,376,552 new shares.
- Review the full text of the Share Purchase Agreement (Exhibit 10.1) for specific terms and conditions.